Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target upped by equities researchers at The Goldman Sachs Group from $50.00 to $85.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the biotechnology company’s stock. The Goldman Sachs Group’s target price would indicate a potential upside of 30.77% from the company’s current price.

Other equities analysts have also issued reports about the company. Chardan Capital upped their target price on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday. HC Wainwright lifted their price target on Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Bank of America upped their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Piper Sandler boosted their target price on shares of Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $71.89.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $65.00 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86. The firm has a market cap of $8.83 billion, a PE ratio of -812.40 and a beta of 1.21. The firm has a 50 day simple moving average of $56.79 and a 200-day simple moving average of $36.15. Arrowhead Pharmaceuticals has a 1-year low of $9.57 and a 1-year high of $76.76.

Insider Activity

In related news, Director Adeoye Y. Olukotun sold 10,000 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $67.66, for a total value of $676,600.00. Following the completion of the sale, the director directly owned 33,600 shares in the company, valued at approximately $2,273,376. This represents a 22.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mauro Ferrari sold 7,530 shares of the firm’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $70.00, for a total value of $527,100.00. Following the sale, the director owned 69,053 shares in the company, valued at approximately $4,833,710. The trade was a 9.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 510,836 shares of company stock worth $33,603,060 in the last quarter. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ARWR. Royal Bank of Canada lifted its stake in shares of Arrowhead Pharmaceuticals by 30.2% in the first quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock worth $576,000 after acquiring an additional 10,496 shares in the last quarter. AQR Capital Management LLC purchased a new stake in Arrowhead Pharmaceuticals during the 1st quarter worth approximately $514,000. Dynamic Technology Lab Private Ltd raised its position in shares of Arrowhead Pharmaceuticals by 40.9% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 26,969 shares of the biotechnology company’s stock valued at $343,000 after purchasing an additional 7,827 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Arrowhead Pharmaceuticals by 34.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock valued at $22,189,000 after purchasing an additional 447,456 shares in the last quarter. Finally, Empowered Funds LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock valued at $194,000 after buying an additional 979 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

More Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Several firms raised price targets (Goldman Sachs to $85, Morgan Stanley to $81, Chardan to $80), signaling institutional confidence in Arrowhead’s pipeline and providing upside narrative for the stock. These upgrades can support medium-term demand. Analyst Price Target Raises
• Positive Sentiment: Arrowhead published interim results and slides on obesity candidates and treatment advances — clinical progress that supports the company’s long-term value proposition and could justify higher valuations if follow-up data confirm benefits. Interim Results
• Neutral Sentiment: Unusually high options volume has been reported, indicating increased speculative or hedging activity; this can amplify intraday moves but does not by itself change fundamentals. Monitor option flow for directional bias. Options Volume
• Negative Sentiment: Arrowhead priced an upsized offering of $625M in 0.00% convertible senior notes due 2032 and concurrent common/pre‑funded-warrant sales at $64.50 per share — a significant capital raise that may dilute existing shareholders and pressure the stock near-term despite extending runway. Offering Details
• Negative Sentiment: Multiple insider sell transactions were reported (executives/officers selling tens of thousands of shares), which can be interpreted negatively by the market even if sales are routine or planned. Insider Sales

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.